ReviewNutrients2023
Nutritional Strategies to Prevent Muscle Loss and Sarcopenia in Chronic Kidney Disease: What Do We Currently Know?
Review in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 58 citations in OpenAlex.
- Electroacupuncture Treatment on Sarcopenia in Patients Undergoing Maintenance Haemodialysis: An Effective Therapy.Journal of cachexia, sarcopenia and muscle · 2026Trial
- Association of low calf circumference and underweight with sarcopenia in older adults with chronic kidney disease: a cross-sectional study.Renal failure · 2026Article
- Development of a Simple Formula for Identifying Reduced Fat-Free Mass in Health Screening Participants.Journal of clinical medicine · 2026Article
- Podocyte Metabolic Reprogramming and Targeted Therapy.Journal of the American Society of Nephrology : JASN · 2026Review
- Adherence to the EAT-Lancet diet and risk of chronic kidney disease among middle-aged and older adults: insights from two nationwide cohort studies.Nutrition journal · 2026Article
- Comprehensive Conservative Management as Rescue Therapy After Haemodialysis Failure: Two Case Reports.Clinics and practice · 2026Article
- Predictive model of sarcopenia in chronic kidney disease: an integrated approach of bioinformatics, machine learning, and clinical validation.Frontiers in physiology · 2026Article
- Muscle ultrasound and shear wave elastography for screening sarcopenia in patients undergoing maintenance hemodialysis: a prospective study.Frontiers in medicine · 2026Article
- Urinary metabolomics identifies isoleucine as a prognostic biomarker for progression of diabetic kidney disease.Frontiers in endocrinology · 2026Article
- Association between the serum creatine kinase level and all-cause mortality in centenarians: a prospective cohort study in China.Frontiers in endocrinology · 2026Article
- Assessing genetic causal relationship between milk fat content and chronic kidney disease: a two-sample Mendelian randomization study.Renal failure · 2025Article
- The current clinical management of muscle wasting in hemodialysis patients with end-stage renal disease.International urology and nephrology · 2025Review
- Are we giving too much weight to lean mass loss?Molecular metabolism · 2025Review
- Food Frequency Questionnaire to Estimate Dietary Adherence in Hemodialysis Patients: A Pilot Study.Nutrients · 2025Article
- The association between hand grip strength and chronic kidney disease progression: insights from SMP-CKD studies.International urology and nephrology · 2025Observational
- Chinese Expert Consensus on Standardized Outpatient Management of Sarcopenia in the Elderly (2024).Aging medicine (Milton (N.S.W)) · 2025Article
- Correlation Between Sarcopenia and Oral Health in Patients on Chronic Hemodialysis.Life (Basel, Switzerland) · 2025Article
- Inhibiting Myostatin Expression by the Antisense Oligonucleotides Improves Muscle Wasting in a Chronic Kidney Disease Mouse Model.International journal of molecular sciences · 2025Article
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Loss of muscle mass is an extremely frequent complication in patients with chronic kidney disease (CKD). The etiology of muscle loss in CKD is multifactorial and may depend on kidney disease itself, dialysis, the typical chronic low-grade inflammation present in patients with chronic kidney disease, but also metabolic acidosis, insulin resistance, vitamin D deficiency, hormonal imbalances, amino acid loss during dialysis, and reduced dietary intake. All these conditions together increase protein degradation, decrease protein synthesis, and lead to negative protein balance. Aging further exacerbates sarcopenia in CKD patients. Nutritional therapy, such as protein restriction, aims to manage uremic toxins and slow down the progression of CKD. Low-protein diets (LPDs) and very low-protein diets (VLPDs) supplemented with amino acids or ketoacids are commonly prescribed. Energy intake is crucial, with a higher intake associated with maintaining a neutral or positive nitrogen balance. Adequate nutritional and dietary support are fundamental in preventing nutritional inadequacies and, consequently, muscle wasting, which can occur in CKD patients. This review explores the causes of muscle loss in CKD and how it can be influenced by nutritional strategies aimed at improving muscle mass and muscle strength.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.